These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28753810)

  • 21. Cancer of the Prostate Risk Assessment (CAPRA) Preoperative Score Versus Postoperative Score (CAPRA-S): ability to predict cancer progression and decision-making regarding adjuvant therapy after radical prostatectomy.
    Seo WI; Kang PM; Kang DI; Yoon JH; Kim W; Chung JI
    J Korean Med Sci; 2014 Sep; 29(9):1212-6. PubMed ID: 25246738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
    Karnes RJ; Choeurng V; Ross AE; Schaeffer EM; Klein EA; Freedland SJ; Erho N; Yousefi K; Takhar M; Davicioni E; Cooperberg MR; Trock BJ
    Eur Urol; 2018 Feb; 73(2):168-175. PubMed ID: 28400167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.
    Böttcher R; Dulla K; van Strijp D; Dits N; Verhoef EI; Baillie GS; van Leenders GJ; Houslay MD; Jenster G; Hoffmann R
    Oncotarget; 2016 Oct; 7(43):70669-70684. PubMed ID: 27683107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
    Cooperberg MR; Broering JM; Carroll PR
    J Natl Cancer Inst; 2009 Jun; 101(12):878-87. PubMed ID: 19509351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The CAPRA&PDE4D5/7/9 Prognostic Model Is Significantly Associated with Adverse Post-Surgical Pathology Outcomes.
    Gulliver C; Huss S; Semjonow A; Baillie GS; Hoffmann R
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.
    Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N
    Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone.
    Swanson GP; Lenz L; Stone S; Cohen T
    Prostate; 2021 Mar; 81(4):261-267. PubMed ID: 33475174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
    Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
    PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis.
    Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Albersen M; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Van Der Poel H; Walz J; De Meerleer G; Bossi A; Haustermans K; Van Poppel H; Spahn M; Joniau S;
    Eur Urol Focus; 2018 Apr; 4(3):369-375. PubMed ID: 28753838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
    Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifying the Most Informative Prediction Tool for Cancer-specific Mortality After Radical Prostatectomy: Comparative Analysis of Three Commonly Used Preoperative Prediction Models.
    Boehm K; Larcher A; Beyer B; Tian Z; Tilki D; Steuber T; Karakiewicz PI; Heinzer H; Graefen M; Budäus L
    Eur Urol; 2016 Jun; 69(6):1038-43. PubMed ID: 26272236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series.
    Loeb S; Carvalhal GF; Kan D; Desai A; Catalona WJ
    Urol Oncol; 2012 Sep; 30(5):584-9. PubMed ID: 20822930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Personalized prediction of tumor response and cancer progression on prostate needle biopsy.
    Donovan MJ; Khan FM; Fernandez G; Mesa-Tejada R; Sapir M; Zubek VB; Powell D; Fogarasi S; Vengrenyuk Y; Teverovskiy M; Segal MR; Karnes RJ; Gaffey TA; Busch C; Haggman M; Hlavcak P; Freedland SJ; Vollmer RT; Albertsen P; Costa J; Cordon-Cardo C
    J Urol; 2009 Jul; 182(1):125-32. PubMed ID: 19450827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
    Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
    J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy.
    Freedland SJ; Choeurng V; Howard L; De Hoedt A; du Plessis M; Yousefi K; Lam LL; Buerki C; Ra S; Robbins B; Trabulsi EJ; Shah NL; Abdollah F; Feng FY; Davicioni E; Dicker AP; Karnes RJ; Den RB
    Eur Urol; 2016 Oct; 70(4):588-596. PubMed ID: 26806658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome.
    Ng CK; Moussa M; Downey DB; Chin JL
    J Urol; 2007 Oct; 178(4 Pt 1):1253-7; discussion 1257. PubMed ID: 17698104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.